Arovella Therapeutics Ltd. announced that Strides Pharma Global Pte Ltd. (Strides) has indicated its intention to cease the Development, Licence and Supply Agreement (Agreement) that was entered into 8 November 2018. Strides cited a change in market conditions, which have made the project unviable from their perspective as their primary reason to cease the Agreement. Arovella has agreed to terminate the Agreement under the relevant provisions contained in the Agreement and the Company notes that there is no cost impact to Arovella or immediate impact on revenue streams. In conjunction with the termination, Arovella has reviewed the operations of the business and will restructure the reformulation group to match the reduced requirements for reformulation project work.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.135 AUD | 0.00% |
|
+3.85% | +17.39% |
13/06 | Arovella Therapeutics, Teva Pharmaceuticals End ZolpiMist License Agreement | MT |
05/06 | Arovella Therapeutics Completes Process Development for ALA-101 Manufacturing; Shares Jump 9% | MT |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+17.39% | 93.74M | |
+40.29% | 53.67B | |
+33.67% | 38.86B | |
-7.72% | 38.76B | |
-10.77% | 27.27B | |
+12.09% | 25.91B | |
-17.72% | 20.29B | |
+34.65% | 12.78B | |
+29.99% | 12.18B | |
-3.02% | 11.96B |
- Stock Market
- Equities
- ALA Stock
- News Arovella Therapeutics Limited
- Arovella Therapeutics Limited Provides Sumatriptan Update